E-LIB Suche - Ergebnisse für: Henríquez, I.

1

PD-0913 Local treatment to the primary tumor and PSA change..:

Lopez Campos, F. ; Lorente, D. ; Llacer-Pérez, C....
Radiotherapy and Oncology. 161 (2021) - p. S755-S756 , 2021

Link: https://doi.org/10.1016/..

2

Age, Gleason Score, and PSA are important prognostic factor..:

Valero, J. ; Peleteiro, P. ; Henríquez, I....
Clinical and Translational Oncology. 22 (2020) 8 - p. 1378-1389 , 2020

Link: https://doi.org/10.1007/..

3

Survival after biochemical failure in prostate cancer treat..:

González-San Segundo, C. ; Jové, J. ; Zapatero, A....
Clinical and Translational Oncology. 21 (2019) 8 - p. 1044-1051 , 2019

Link: https://doi.org/10.1007/..

4

Multiparametric MRI for prostate cancer: a national survey ..:

The Urological Tumours Working Group of the Spanish Society of Radiation Oncology (URONCOR/SEOR) ; Couñago, F. ; Sancho, G...
Clinical and Translational Oncology. 20 (2018) 11 - p. 1484-1491 , 2018

Link: https://doi.org/10.1007/..

5

Consensus on management of castration-resistant prostate ca..:

Expert Panel for the Consensus on Management of Castration-Resistant Prostate Cancer 2017, Urological Tumours Working Group (URONCOR), Spanish Society of Radiation Oncology (SEOR) ; Gómez-Caamaño, A. ; González-San Segundo, C....
Clinical and Translational Oncology. 21 (2018) 4 - p. 420-432 , 2018

Link: https://doi.org/10.1007/..

6

Survival after Biochemical Failure in Prostate Cancer Treat..:

González, C. ; Jove-Teixido, J. ; Zapatero, A....
International Journal of Radiation Oncology*Biology*Physics. 102 (2018) 3 - p. e113 , 2018

Link: https://doi.org/10.1016/..

7

Outcomes and prognostic factors in intermediate-risk prosta..:

Hervás, A. ; Pastor, J. ; González, C....
Clinical and Translational Oncology. 21 (2018) 7 - p. 900-909 , 2018

Link: https://doi.org/10.1007/..

8

Consensus statement on definition, diagnosis, and managemen..:

Henríquez, I. ; Rodríguez-Antolín, A. ; Cassinello, J....
Clinical and Translational Oncology. 20 (2017) 3 - p. 392-401 , 2017

Link: https://doi.org/10.1007/..

9

The number of risk factors is the strongest predictor of pr..:

Gomez-Iturriaga, A. ; Cabeza, Á. ; Pastor, J....
Clinical and Translational Oncology. 18 (2016) 10 - p. 1026-1033 , 2016

Link: https://doi.org/10.1007/..

10

Intermittent versus continuous androgen deprivation therapy..:

Casas, F. ; Henríquez, I. ; Bejar, A....
Clinical and Translational Oncology. 19 (2016) 3 - p. 373-378 , 2016

Link: https://doi.org/10.1007/..

11

Needle track recurrence after transrectal prostate biopsy d..:

Garcia-Bennett, J. ; Henríquez, I. ; Zugazaga Cortazar, A..
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 34 (2015) 2 - p. 128-129 , 2015

Link: https://doi.org/10.1016/..

12

Hypofractionated High-Dose-Rate Brachytherapy in Nonmelanom..:

Arenas, M. ; Arguís, M. ; Díez-Presa, L....
International Journal of Radiation Oncology*Biology*Physics. 90 (2014) 1 - p. S753-S754 , 2014

Link: https://doi.org/10.1016/..

13

Patterns of care and outcome for patients with glioblastoma..:

Graus, F. ; Bruna, J. ; Pardo, J....
Neuro-Oncology. 15 (2013) 6 - p. 797-805 , 2013

Link: https://doi.org/10.1093/..

14

Multi-institutional Outcomes Following External Beam Radiat..:

Gomez-Iturriaga, A. ; Cabeza, M. ; Pastor, J....
International Journal of Radiation Oncology*Biology*Physics. 87 (2013) 2 - p. S367 , 2013

Link: https://doi.org/10.1016/..

15

Construction of Nomograms for Predicting the Development of..:

Torrecilla, J. ; Boladeras, A. ; Cabeza, M.A....
International Journal of Radiation Oncology*Biology*Physics. 84 (2012) 3 - p. S376-S377 , 2012

Link: https://doi.org/10.1016/..